The purpose of this pilot study is to evaluate a new decision support tool (“COAST”), designed for people with advanced breast cancer. This tool is intended to support patients and their providers to have meaningful conversations regarding their care and treatment. Through this study, we hope to better understand and improve our support of patients in making informed choices about their treatment.

The COAST decision support tool is available in a booklet version and a website based on preference. 

This study is being done to determine if the addition of a high dose of radiation therapy extends or improves quality of life in patients with locally advanced pancreatic cancer. Locally advanced means that the cancer cannot be removed by surgery but also has not spread to other parts of the body and the tumor has either responded or is stable after chemotherapy.

We are doing this study because we want to find out if this approach is better or worse than the usual approach, which is defined as care most people get for locally advanced pancreatic cancer. 

This is a prospective observational study of clinical and patient-provided outcomes for individuals with sex chromosome aneuploidy (SCA) conditions throughout the lifespan: the GALAXY Registry.

This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).
   
The BioHealx implant is a small coil made of a material that is absorbed by the body over time. It has been designed to close the fistula. As the fistula heals, the implant gradually dissolves from the body.
   

 This clinical trial is for men and women with HR+/HER2− stage II or III eBC patients treated with the study drugs, i.e., Kisqali® (ribociclib) + endocrine therapy (ET), or Verzenio® (abemaciclib) + ET, as per local label in routine clinical care settings.
   
The purpose of this study to learn more about how people with early breast cancer feel and respond when treated with either Kisqali® (ribociclib) plus ET or Verzenio® (abemaciclib) plus ET treatment.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM.
   

This research study is being conducted to better understand how the Eye90 radiation treatment affects liver tumors.

After a patient undergoes transplant surgery, the removed liver tissue will be examined using detailed imaging and microscope techniques to study how well the treatment worked and how the radiation particles were distributed in the tumor.

No additional tests, procedures, or visits are required for participation in this study.

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches).

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches).